GSK has claimed its second breakthrough designation from the FDA for antibody-drug conjugate GSK5764227, which it licensed from China's Hansoh Pharma in a $1.7 billion deal. The status has been given ...
Eli Lilly has signed an agreement with Hims & Hers that will see its weight-loss therapies Zepbound and Foundayo sold ...
Moderna's mRNA-1469 and ChAdOx1, developed by the University of Oxford in partnership with the Serum Institute of India, ...
For years, success in kidney disease has largely been measured by how much its progression could be slowed. Newer treatments ...
Rezera, formerly known as NodThera until a rebrand earlier this year, has announced the terms of its planned Nasdaq IPO, ...
Patients with muscle-invasive bladder cancer can now receive NHS treatment with a regimen of MSD's Keytruda and Astellas' ...
Theramex, a London, UK-based specialty pharma company focusing on women's health, is changing hands in a deal reportedly ...
Novo has raised its financial guidance for 2026 on the back of rising sales of its oral weight-loss therapy Wegovy, which ...
T-Therapeutics and Alethio Therapeutics – have raised $133 million and $90 million, respectively, in an impressive pair of ...
While praising the breadth of its pipeline, AstraZeneca has launched a three-year cost-cutting programme that will aim to ...
In oncology, time is not simply a measure of care; it is a clinical variable – and increasingly a therapeutic challenge.
The WuXi agreement gives Fresenius "full strategic flexibility" to choose which biosimilar candidates to develop and gives ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results